These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 29357260)

  • 1. Mitochondrial Targeted Doxorubicin-Triphenylphosphonium Delivered by Hyaluronic Acid Modified and pH Responsive Nanocarriers to Breast Tumor: in Vitro and in Vivo Studies.
    Liu HN; Guo NN; Wang TT; Guo WW; Lin MT; Huang-Fu MY; Vakili MR; Xu WH; Chen JJ; Wei QC; Han M; Lavasanifar A; Gao JQ
    Mol Pharm; 2018 Mar; 15(3):882-891. PubMed ID: 29357260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
    Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
    Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin derivative loaded acetal-PEG-PCCL micelles for overcoming multidrug resistance in MCF-7/ADR cells.
    Zhong XC; Xu WH; Wang ZT; Guo WW; Chen JJ; Guo NN; Wang TT; Lin MT; Zhang ZT; Lu YY; Yang QY; Han M; Xu DH; Gao JQ
    Drug Dev Ind Pharm; 2019 Sep; 45(9):1556-1564. PubMed ID: 31271317
    [No Abstract]   [Full Text] [Related]  

  • 4. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial targeted doxorubicin derivatives delivered by ROS-responsive nanocarriers to breast tumor for overcoming of multidrug resistance.
    Zhong XC; Shi MH; Liu HN; Chen JJ; Wang TT; Lin MT; Zhang ZT; Zhou Y; Lu YY; Xu WH; Gao JQ; Xu DH; Han M; Chen YD
    Pharm Dev Technol; 2021 Jan; 26(1):21-29. PubMed ID: 33070673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial delivery of doxorubicin via triphenylphosphine modification for overcoming drug resistance in MDA-MB-435/DOX cells.
    Han M; Vakili MR; Soleymani Abyaneh H; Molavi O; Lai R; Lavasanifar A
    Mol Pharm; 2014 Aug; 11(8):2640-9. PubMed ID: 24811541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folate-mediated mitochondrial targeting with doxorubicin-polyrotaxane nanoparticles overcomes multidrug resistance.
    Wang H; Yin H; Yan F; Sun M; Du L; Peng W; Li Q; Feng Y; Zhou Y
    Oncotarget; 2015 Feb; 6(5):2827-42. PubMed ID: 25605018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
    Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
    Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondria and Nucleus Dual Delivery System To Overcome DOX Resistance.
    Cui H; Huan ML; Ye WL; Liu DZ; Teng ZH; Mei QB; Zhou SY
    Mol Pharm; 2017 Mar; 14(3):746-756. PubMed ID: 28146635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of Mitochondrial Cell Death and Reversal of Anticancer Drug Resistance via Nanocarriers Composed of a Triphenylphosphonium Derivative of Tocopheryl Polyethylene Glycol Succinate.
    Singh Y; Viswanadham KKDR; Pawar VK; Meher J; Jajoriya AK; Omer A; Jaiswal S; Dewangan J; Bora HK; Singh P; Rath SK; Lal J; Mishra DP; Chourasia MK
    Mol Pharm; 2019 Sep; 16(9):3744-3759. PubMed ID: 31441308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Facile strategy by hyaluronic acid functional carbon dot-doxorubicin nanoparticles for CD44 targeted drug delivery and enhanced breast cancer therapy.
    Li J; Li M; Tian L; Qiu Y; Yu Q; Wang X; Guo R; He Q
    Int J Pharm; 2020 Mar; 578():119122. PubMed ID: 32035259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced Reactive Oxygen Species Generation by Mitochondria Targeting of Anticancer Drug To Overcome Tumor Multidrug Resistance.
    Liu Y; Zhou Z; Lin X; Xiong X; Zhou R; Zhou M; Huang Y
    Biomacromolecules; 2019 Oct; 20(10):3755-3766. PubMed ID: 31465208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced chemotherapeutic efficacy of the low-dose doxorubicin in breast cancer via nanoparticle delivery system crosslinked hyaluronic acid.
    Wang Q; Zhong Y; Liu W; Wang Z; Gu L; Li X; Zheng J; Du H; Zhong Z; Xie F
    Drug Deliv; 2019 Dec; 26(1):12-22. PubMed ID: 30691317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy.
    Shao Y; Luo W; Guo Q; Li X; Zhang Q; Li J
    Drug Des Devel Ther; 2019; 13():2043-2055. PubMed ID: 31388296
    [No Abstract]   [Full Text] [Related]  

  • 15. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
    Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
    Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor acidity activated triphenylphosphonium-based mitochondrial targeting nanocarriers for overcoming drug resistance of cancer therapy.
    Yu H; Li JM; Deng K; Zhou W; Wang CX; Wang Q; Li KH; Zhao HY; Huang SW
    Theranostics; 2019; 9(23):7033-7050. PubMed ID: 31660085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin.
    Qiu L; Qiao M; Chen Q; Tian C; Long M; Wang M; Li Z; Hu W; Li G; Cheng L; Cheng L; Hu H; Zhao X; Chen D
    Biomaterials; 2014 Dec; 35(37):9877-9887. PubMed ID: 25201738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles.
    Yu P; Yu H; Guo C; Cui Z; Chen X; Yin Q; Zhang P; Yang X; Cui H; Li Y
    Acta Biomater; 2015 Mar; 14():115-24. PubMed ID: 25498306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Robust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materials.
    Sun B; Deng C; Meng F; Zhang J; Zhong Z
    Acta Biomater; 2016 Nov; 45():223-233. PubMed ID: 27576338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular self-disassemble polysaccharide nanoassembly for multi-factors tumor drug resistance modulation of doxorubicin.
    Xiong H; Ni J; Jiang Z; Tian F; Zhou J; Yao J
    Biomater Sci; 2018 Aug; 6(9):2527-2540. PubMed ID: 30105340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.